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Abstract
BACKGROUND—Prosurvival signaling kinases inhibit glycogen synthase kinase-3β (GSK-3β)
activity and stimulate apoptotic protein p53 degradation. Helium produces cardioprotection by
activating prosurvival kinases, but whether GSK and p53 inhibition mediate this process is unknown.
We tested the hypothesis that inhibition of GSK or p53 lowers the threshold of helium
cardioprotection via a mitochondrial permeability transition pore (mPTP)-dependent mechanism.
METHODS—Rabbits (n = 85) instrumented for hemodynamic measurement and subjected to a 30
min left anterior descending coronary artery (LAD) occlusion and 3 h reperfusion received 0.9%
saline (control), or 1, 3, or 5 cycles of 70% helium-30% oxygen administered for 5 min interspersed
with 5 min of an air-oxygen mixture (fraction of inspired oxygen concentration = 0.30) before LAD
occlusion. Other rabbits received the GSK inhibitor SB 216763 (SB21; 0.2 or 0.6 mg/kg), the p53
inhibitor pifithrin-α (PIF; 1.5 or 3.0 mg/kg), or SB21 (0.2 mg/kg) or PIF (1.5 mg/kg) plus helium (1
cycle) before LAD occlusion in the presence or absence of the mPTP opener atractyloside (5 mg/
kg).
RESULTS—Helium reduced (P < 0.05) myocardial infarct size (35 ± 6 [n = 7], 25 ± 4 [n = 7], and
20 ± 3% [n = 6] of area at risk, 1, 3, and 5 cycles, respectively) compared with control (44 ± 6% [n
= 7]). SB21 (0.6 [n = 7] but not 0.2 mg/kg [n = 6]) and PIF (3.0 [n = 6] but not 1.5 mg/kg [n = 7])
also reduced necrosis. SB21 (0.2 mg/kg) or 1.5 mg/kg PIF (1.5 mg/kg) plus helium (1 cycle; n = 6
per group) decreased infarct size to an equivalent degree as three cycles of helium alone, and this
cardioprotection was blocked by atractyloside (n = 7 per group).
CONCLUSIONS—Inhibition of GSK or p53 lowers the threshold of helium-induced
preconditioning via a mPTP-dependent mechanism in vivo.
Administration of noble gases before prolonged coronary artery occlusion and reperfusion
protects myocardium against infarction.1,2 Our laboratory recently demonstrated that the
cardioprotective effects of brief, repetitive exposure to the nonanesthetic noble gas helium in
vivo are mediated by activation of prosurvival signaling kinases (including
phosphotidylinositol-3-kinase [PI3K], extracellular signal-regulated kinases [Erk1/2], and
mammalian target of rapamycin-70-kDa ribosomal protein s6 kinase [mTOR/p70s6K]) and
inhibition of the mitochondrial permeability transition pore (mPTP).1 The β isoform of
glycogen synthase kinase-3β (GSK-3β) is an important mediator of cellular function3 whose
activation has been implicated in the pathogenesis of diabetes mellitus4 and Alzheimer’s
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disease.5 In contrast, GSK-3β inhibition has been shown to play a critical role in ischemic,
pharmacologic, and anesthetic pre- and postconditioning.6–12 Several prosurvival kinases
(e.g., PI3K, mTOR/p70s6K, protein kinase C) converge on and inhibit GSK-3β, thereby
favorably modulating mPTP and producing cardioprotection.13 Activated GSK-3β binds to
and promotes the actions of the apoptotic protein p53,14 and this latter enzyme also
independently facilitates mPTP opening through its interactions with another apoptotic moiety,
Bax.15 Thus, it is not surprising that a role for inhibition of p53 in myocardial and neural
protection against cellular injury has also been described.16–18 Whether GSK or p53 inhibition
mediates the protective effects of helium is unknown. We tested the hypothesis that inhibition
of GSK or p53 lowers the threshold of helium cardioprotection via an mPTP-dependent
mechanism in vivo.
METHODS
All experimental procedures and protocols used in this investigation were reviewed and
approved by the Animal Care and Use Committee of the Medical College of Wisconsin.
Furthermore, all conformed to the Guiding Principles in the Care and Use of Animals of the
American Physiologic Society and were in accordance with the Guide for the Care and Use
of Laboratory Animals.
Experimental Preparation
Male New Zealand white rabbits weighing between 2.5 and 3.0 kg were anesthetized with IV
sodium pentobarbital (30 mg/kg) as previously described.1 Additional doses of pentobarbital
were titrated as required to assure that pedal and palpebral reflexes were absent throughout the
experiment. Briefly, a tracheostomy was performed through a midline incision, and each rabbit
was ventilated with positive pressure using an air-oxygen mixture (fractional inspired oxygen
concentration = 0.30). Arterial blood gas tensions and acid-base status were maintained within
a normal physiological range by adjusting the respiratory rate or tidal volume throughout the
experiment. A pulse oximeter was placed on the right hindpaw of each rabbit for measurement
of continuous arterial oxygen saturation. Heparin-filled catheters were positioned in the right
carotid artery and the left jugular vein for measurement of arterial blood pressure and fluid or
drug administration, respectively. Maintenance fluids (0.9% saline; 15 mL · kg−1 · min−1) were
continued for the duration of each experiment. A thoracotomy was performed at the left fourth
intercostal space, and the heart was suspended in a pericardial cradle. A prominent branch of
the left anterior descending coronary artery (LAD) was identified, and a silk ligature was placed
around this vessel approximately halfway between the base and the apex for the production of
coronary artery occlusion and reperfusion. IV heparin (500 U) was administered immediately
before LAD occlusion. Coronary artery occlusion was verified by the presence of epicardial
cyanosis and regional dyskinesia in the ischemic zone, and reperfusion was confirmed by
observing an epicardial hyperemic response. Systemic hemo-dynamics was continuously
recorded on a polygraph throughout each experiment.
Experimental Protocol
The experimental design is illustrated in Figure 1. Baseline hemodynamics and arterial blood
gas tensions were recorded 30 min after instrumentation was completed. All rabbits underwent
a 30 min LAD occlusion after 3 h of reperfusion. In 12 separate groups, rabbits (n = 85) were
randomly assigned to receive 0.9% saline (control), 1, 3, or 5 cycles of 70% helium-30%
oxygen administered for 5 min interspersed with 5 min of an air-oxygen mixture (fractional
inspired oxygen concentration = 0.30), the selective GSK inhibitor SB 216763 (SB21; 0.2 or
0.6 mg/kg), the p53 inhibitor selective pifithrin-α (1.5 or 3.0 mg/kg), or the combination of
SB21 (0.2 mg/kg) or pifithrin-α (1.5 mg/kg) and 1 cycle of 70% helium-30% oxygen before
LAD occlusion in the absence and presence of the mPTP opener atractyloside (5 mg/kg). SB21
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and atractyloside were dissolved in dimethyl-sulfoxide and administered by IV infusion 30
min before coronary occlusion. Pifithrin-α was dissolved in dimethylsulfoxide and
administered by intraperitoneal injection 30 min before LAD occlusion. We have previously
shown that the lower doses of SB21 and pifithrin-α do not produce hemodynamic effects nor
affect infarct size in an identical rabbit model.12,18 We have also shown that the dose of
atractyloside used in the current investigation is devoid of hemodynamic effects, does not alter
the extent of myocardial necrosis compared with 0.9% saline when administered alone, and
abolishes reductions in infarct size produced by the selective mPTP inhibitor cyclosporin A.
19 Dimethylsulfoxide alone also did not affect infarct size in rabbits.20
Measurement of Myocardial Infarct Size
Myocardial infarct size was measured as previously described.1 Briefly, the LAD was
reoccluded at the completion of each experiment and 3 mL of patent blue dye was injected IV.
The left ventricular area at risk for infarction was separated from surrounding normal areas
(stained blue), and the two regions were incubated at 37°C for 20 min in 1% 2,3,5-
triphenyltetrazolium chloride in 0.1 M phosphate buffer adjusted to pH 7.4. Infarcted and
noninfarcted myocardium within the area at risk were carefully separated and weighed after
storage overnight in 10% formaldehyde. Myocardial infarct size was expressed as a percentage
of the area at risk. Rabbits that developed intractable ventricular fibrillation and those with an
area at risk <15% of total left ventricular mass were excluded from subsequent analysis.
Statistical Analysis
A power analysis indicated that a group size of n≥6 was required for a minimal difference in
infarct size of 20% (α error <0.05; β error <20%) with a power of 95%. Statistical analysis of
data within and between groups was performed with analysis of variance for repeated measures
followed by Bonferroni’s modification of Student’s t-test. Changes were considered
statistically significant when P < 0.05. All data are expressed as mean ± SD (SD).
RESULTS
Eighty-five rabbits were instrumented to obtain 78 successful infarct size experiments. Four
rabbits were excluded because the left ventricular area at risk was <15% of the total left
ventricular mass. Three rabbits were excluded because intractable ventricular fibrillation
occurred during coronary artery occlusion. Arterial blood gas tensions and acid-base status
were maintained within the physiologic range during administration of helium in all groups
(data not shown). No differences among groups were observed. Arterial oxygen saturation
remained at 100% during and after administration of helium with or without other drug
interventions (data not shown). Baseline systemic hemodynamics were similar among groups
(Table 1). No changes in hemodynamics were observed during administration of helium. SB21,
pifithrin-α, and atractyloside did not affect hemodynamics in the absence or presence of helium.
Significant (P < 0.05) decreases in rate–pressure product occurred during reperfusion in all
experimental groups except for rabbits receiving 1 cycle of helium, 1.5 mg/kg pifithrin-α, and
5 mg/kg atractyloside.
Body weight, left ventricular mass, area at risk weight, and the ratio of area at risk to left
ventricular mass were similar among groups (Table 2). Helium significantly (P < 0.05) reduced
infarct size (35 ± 6, 25 ± 4, and 20% ± 3%, 1, 3, and 5 cycles, respectively, of left ventricular
area at risk; Fig. 2) compared with control rabbits (44% ± 6%). SB21 (0.6 but not 0.2 mg/kg)
and pifithrin-α (3.0 but not 1.5 mg/kg) alone also reduced infarct size (21 ± 2, 45 ± 2, 24 ± 1,
and 46% ± 2%, respectively). The combination of 0.2 mg/kg SB21 or 1.5 mg/kg pifithrin-α
and 1 cycle of helium decreased infarct size (25 ± 4 and 22% ± 2%, respectively) to an
equivalent degree as 3 cycles of helium exposure alone. The cardioprotective effects of
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combined administration of SB21 or pifithrin-α and helium were abolished by atractyloside
pretreatment (46 ± 3 and 47% ± 2%, respectively).
DISCUSSION
The current results confirm previous observations1 demonstrating that 3 cycles of 5 min 70%
helium-30% oxygen preconditioning interspersed with 5 min washout periods of an air-oxygen
mixture reduce myocardial necrosis after prolonged coronary artery occlusion and reperfusion.
Further, the results indicate for the first time that cardioprotection produced by the
nonanesthetic noble gas is dependent on exposure frequency before ischemia and reperfusion.
Although a single cycle of helium preconditioning produced only a small decrease in infarct
size, progressively larger quantities of myocardium were salvaged from irreversible ischemic
injury as the number of cycles of helium preconditioning increased. The 0.6 and 3.0 mg/kg
doses of SB21 and pifithrin-α, respectively, also reduced infarct size in the current
investigation, confirming that inhibition of GSK or p53 produces cardioprotection.9,12,16,
18 Previous studies have shown that decreases in myocardial necrosis produced by SB21 or
pifithrin-α were unaffected by administration of the selective PI3K antagonist wortmannin, but
were abolished by the mPTP opener atractyloside,12,13,15,18 confirming that that GSK or
p53 inhibition-mediated protection occurs downstream from PI3K and is dependent on the
transition state of the mPTP. The current results also demonstrate that combined administration
of sub-cardioprotective threshold doses of SB21 or pifithrin-α and helium reduce myocardial
infarct size to a similar magnitude as three cycles of helium alone, and further, that these
cardioprotective effects were abolished by atractyloside pretreatment. Thus, the results suggest
that GSK or p53 inhibition lowers the threshold of helium preconditioning in barbiturate-
anesthetized, acutely instrumented rabbits in a mPTP-dependent manner.
A role for GSK-3β inhibition in several forms of cardioprotection against irreversible ischemic
injury has been established.6–11 Reductions in myocardial infarct size during ischemic
preconditioning were associated with phosphorylation of GSK-3β through a PI3K-dependent
mechanism.6 Similarly, GSK-3β inhibition mediated the protective effects of G protein-linked
receptor ligands (e.g., δ1 opioid,7–9 adenosine subtype 3 [A3]10) and volatile anesthetics12,
21,22 administered before ischemia or during early reperfusion. GSK-3β has been shown to
function as a primary regulatory target of prosurvival kinases. Modulation of this enzyme’s
activity appears to play a critical role in determining the transition state of the mPTP upon
reperfusion and thus the extent of subsequent myocardial damage.13 Activation of PI3K and
Erk1/2 and their target mTOR/p70s6K were shown to mediate helium preconditioning in
rabbits.1 Thus, the current results suggest that the cardioprotection produced by the
combination of a single 5 min helium exposure to a subthreshold dose of SB21 may be related
to more pronounced inhibition of GSK-3β by helium-induced activation of these upstream
signaling kinases. However, this conclusion requires qualification because the specific GSK
isoform (α or β) was not identified, nor were GSK-3β phosphorylation or enzyme activity
determined in the current investigation.
The precise mechanism(s) by which GSK-3β inhibition reduces mPTP opening during early
reperfusion and preserves myocardial viability remains to be clearly defined. Activated
GSK-3β was shown to bind and stimulate the actions of the tumor suppressor protein p5314
which, when activated, translocates to mitochondria, opens mPTP through its interactions with
Bax, facilitates the release of cytochrome c, and causes rapid mitochondrial demise.15
Activation of p53 by hypoxia or large quantities of reactive oxygen species23 also produces
cell death by enhancing signaling by24 and increasing transcription of apoptotic proteins.25
In contrast, ischemic preconditioning mitigated increases in p53 expression after hypoxia-
reoxygenation in ventricular myocytes.26 Direct pifithrin-α-induced p53 inhibition or
enhanced degradation of the protein by PI3K-mediated phosphorylation of murine double
Pagel et al. Page 4
Anesth Analg. Author manuscript; available in PMC 2008 October 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
minute 2 (Mdm2) protein protected against ischemic injury.16 Pifithrin-α also enhanced
isoflurane postconditioning.18 Furthermore, transgenic deletion of p53 prevented cardiac
rupture after myocardial infarction.27 Taken together, these data suggest that inhibition of p53
activity or increases in p53 metabolism stimulated by PI3K activation mediates several forms
of cardioprotection. The current results demonstrate that administration of a dose of pifithrin-
α that did not affect infarct size alone lowered the threshold of helium preconditioning in
vivo. This action was blocked by atractyloside, suggesting that the observed reductions in
infarct size were mediated by the combined actions of the helium and selective p53 inhibition
on mPTP. The PI3K downstream target Akt was shown to activate Mdm228 and, thus,
activation of PI3K by helium may facilitate an interaction between phospho-Mdm2 and p53
that leads to the metabolism of the apoptotic protein29 and prevents its detrimental association
with GSK-3β. Ischemic preconditioning was shown to activate Mdm2 and enhance phospho-
Mdm2-p53 binding in a PI3K-dependent manner,16 but whether helium specifically causes
phosphorylation of Mdm2 or produces a similar phospho-Mdm2-p53 interaction was not
specifically examined in the current investigation.
In addition to previously described limitations, the current results must be interpreted within
the constraints of several other potential shortcomings. SB21 and pifithrin-α have been shown
to be selective inhibitors of GSK and p53,30,31 respectively, at the doses used in the current
investigation. Similarly, atractyloside was shown to be a relatively selective mPTP opener.
32 Nevertheless, the possibility that these drugs may have affected the activity of other protein
kinases involved in helium preconditioning cannot be completely excluded. The route and
duration of administration of SB21, pifithrin-α, and atractyloside, and were heterogeneous, and
these pharmacokinetic factors may have influenced the results. Plasma concentrations of SB21,
pifithrin-α, and atractyloside were also not determined. Myocardial infarct size is determined
primarily by the size of the area at risk and the extent of coronary collateral perfusion. The area
at risk expressed as a percentage of total left ventricular mass was similar among groups in the
current investigation, and coronary collateral blood flow was shown to be minimal in rabbits.
Thus, differences in collateral perfusion among groups probably did not account for the
observed results, but coronary collateral blood flow was not specifically quantified. The
reductions in myocardial necrosis produced by helium in the absence or presence of other drug
interventions occurred independent of changes in major determinants of myocardial oxygen
consumption. Nevertheless, coronary venous oxygen tension was not directly measured nor
was myocardial oxygen consumption calculated. Notably, no significant differences in
hemodynamics were observed among groups before and during coronary artery occlusion that
may account for differences in infarct size observed among groups. Finally, the current results
implicating a role for GSK, p53, and mPTP in helium-induced cardioprotection were obtained
in barbiturate-anesthetized, acutely instrumented rabbits. It is unknown whether similar results
occur in other animal species or humans.
In summary, the current results confirm that brief, intermittent administration of helium before
prolonged coronary artery occlusion and reperfusion protects myocardium against infarction
and demonstrate that this helium cardioprotection is dependent on exposure frequency before
ischemia and reperfusion in rabbits. The findings further suggest that GSK or p53 inhibition
lowers the threshold of helium cardio-protection via a mPTP-dependent mechanism in vivo.
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Figure 1.
Schematic illustration depicting the experimental protocol used in the current investigation.
SB21 = SB 216763; PIF = pifithrin-α; ATR = atractyloside.
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Figure 2.
Myocardial infarct size depicted as a percentage of left ventricular area at risk in rabbits
receiving 0.9% saline (control, CON) or 1, 3, or 5 cycles of 70% helium-30% oxygen
administered for 5 min interspersed with 5 min of an air-oxygen mixture (fraction of inspired
oxygen concentration = 0.30; panel A, top). Infarct sizes in rabbits receiving the selective
glycogen synthase kinase inhibitor SB 216763 (SB21, 0.2 or 0.6 mg/kg) and the combination
of one preconditioning cycle of helium and 0.2 mg/kg SB21 in the absence or presence of the
mitochondrial permeability transition pore opener atractyloside (ATR; 5 mg/kg) are depicted
in panel B (middle). Infarct sizes in rabbits receiving the selective p53 inhibitor pifithrin-α
(PIF, 1.5 or 3.0 mg/kg) and the combination of one preconditioning cycle of helium and 1.5
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mg/kg PIF in the absence of presence of ATR (5 mg/kg) are depicted in panel C (bottom). Each
point represents a single experiment. All data are mean ± SD *Significantly (P < 0.05) different
from CON; †Significantly (P < 0.05) different from one cycle of helium pretreatment.
Pagel et al. Page 10
Anesth Analg. Author manuscript; available in PMC 2008 October 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pagel et al. Page 11
Ta
bl
e 
1
H
em
od
yn
am
ic
s
R
ep
er
fu
si
on
 (m
in
)
B
as
el
in
e
In
te
rv
en
tio
n
O
cc
lu
si
on
60
12
0
18
0
H
R
 (m
in
−1
)
  C
O
N
24
9 
± 
40
24
1 
± 
34
24
1 
± 
34
23
7 
± 
21
23
1 
± 
25
22
0 
± 
23
  H
e 
(1
 C
yc
le
)
26
3 
± 
29
25
4 
± 
25
23
9 
± 
18
23
0 
± 
31
*
22
4 
± 
31
*
22
0 
± 
24
*
  H
e 
(3
 C
yc
le
s)
25
1 
± 
33
24
3 
± 
27
22
3 
± 
18
*
21
6 
± 
26
*
20
9 
± 
22
*
19
9 
± 
25
*
  H
e 
(5
 C
yc
le
s)
25
6 
± 
28
24
5 
± 
22
21
8 
± 
20
*
21
7 
± 
14
*
20
4 
± 
9*
19
4 
± 
7*
  S
B
21
 (0
.2
 m
g/
kg
)
27
2 
± 
24
26
5 
± 
23
25
3 
± 
23
24
3 
± 
27
*
23
5 
± 
24
*
22
9 
± 
22
*
  S
B
21
 (0
.6
 m
g/
kg
)
25
9 
± 
31
25
2 
± 
19
23
9 
± 
17
22
7 
± 
14
*
21
8 
± 
22
*
20
9 
± 
25
*
  H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
)
23
2 
± 
10
22
4 
± 
13
22
8 
± 
23
22
2 
± 
28
21
5 
± 
29
20
7 
± 
27
  H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
27
3 
± 
27
26
5 
± 
21
25
7 
± 
16
23
5 
± 
31
23
4 
± 
10
*
22
8 
± 
8*
  P
IF
 (1
.5
 m
g/
kg
)
27
1 
± 
29
25
7 
± 
26
25
9 
± 
26
25
1 
± 
27
*
23
5 
± 
26
*
21
5 
± 
12
*
  P
IF
 (3
.0
 m
g/
kg
)
27
5 
± 
21
24
3 
± 
22
24
3 
± 
22
23
1 
± 
30
*
22
4 
± 
11
*
22
0 
± 
12
*
  H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
)
26
2 
± 
19
23
8 
± 
15
23
7 
± 
22
23
8 
± 
15
22
8 
± 
17
*
21
5 
± 
12
*
  H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
27
4 
± 
24
26
7 
± 
33
25
9 
± 
36
24
9 
± 
47
24
3 
± 
47
24
6 
± 
48
M
A
P 
(m
m
 H
g)
  C
O
N
74
 ±
 7
68
 ±
 8
64
 ±
 8
63
 ±
 6
64
 ±
 6
64
 ±
 7
  H
e 
(1
 C
yc
le
)
71
 ±
 7
75
 ±
 7
67
 ±
 9
67
 ±
 9
68
 ±
 1
2
68
 ±
 1
0
  H
e 
(3
 C
yc
le
s)
77
 ±
 8
82
 ±
 1
2
61
 ±
 1
1
60
 ±
 9
*
63
 ±
 9
*
60
 ±
 7
*
  H
e 
(5
 C
yc
le
s)
65
 ±
 1
1
65
 ±
 9
55
 ±
 9
57
 ±
 4
56
 ±
 6
58
 ±
 5
  S
B
21
 (0
.2
 m
g/
kg
)
61
 ±
 7
63
 ±
 1
0
64
 ±
 5
57
 ±
 5
60
 ±
 7
61
 ±
 7
  S
B
21
 (0
.6
 m
g/
kg
)
67
 ±
 1
1
70
 ±
 1
3
70
 ±
 1
2
64
 ±
 1
1
64
 ±
 1
0
63
 ±
 9
  H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
)
64
 ±
 8
68
 ±
 7
58
 ±
 8
58
 ±
 5
58
 ±
 7
58
 ±
 6
  H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
69
 ±
 1
1
70
 ±
 1
3
60
 ±
 1
2
58
 ±
 1
0
59
 ±
 8
62
 ±
 1
2
  P
IF
 (1
.5
 m
g/
kg
)
69
 ±
 7
74
 ±
 9
68
 ±
 1
1
60
 ±
 5
60
 ±
 8
63
 ±
 1
0
  P
IF
 (3
.0
 m
g/
kg
)
64
 ±
 6
70
 ±
 1
2
54
 ±
 1
6
56
 ±
 9
58
 ±
 9
59
 ±
 1
1
  H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
)
65
 ±
 9
73
 ±
 1
3
69
 ±
 1
2
59
 ±
 7
65
 ±
 1
0
60
 ±
 8
  H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
69
 ±
 1
2
71
 ±
 1
1
65
 ±
 8
64
 ±
 1
1
61
 ±
 9
61
 ±
 1
0
R
PP
 (m
in
−1
 · 
m
m
 H
g 
· 1
0−
3 )
  C
O
N
21
.1
 ±
 4
.3
19
.2
 ±
 3
.7
17
.9
 ±
 3
.2
18
.0
 ±
 3
.0
17
.7
 ±
 2
.5
16
.4
 ±
 2
.3
*
  H
e 
(1
 C
yc
le
)
20
.7
 ±
 1
.4
21
.2
 ±
 2
.5
18
.0
 ±
 2
.8
17
.6
 ±
 4
.3
17
.4
 ±
 4
.6
16
.7
 ±
 3
.2
*
  H
e 
(3
 C
yc
le
s)
21
.9
 ±
 4
.2
22
.7
 ±
 4
.1
16
.0
 ±
 3
.8
*
15
.3
 ±
 3
.7
*
15
.6
 ±
 2
.6
*
14
.1
 ±
 4
.9
*
  H
e 
(5
 C
yc
le
s)
19
.1
 ±
 3
.3
18
.1
 ±
 2
.6
14
.1
 ±
 2
.4
*
14
.4
 ±
 1
.0
*
13
.4
 ±
 1
.3
*
13
.1
 ±
 1
.3
*
  S
B
21
 (0
.2
 m
g/
kg
)
19
.3
 ±
 2
.7
19
.5
 ±
 3
.8
18
.9
 ±
 2
.7
16
.2
 ±
 2
.2
16
.5
 ±
 2
.5
16
.2
 ±
 2
.1
*
  S
B
21
 (0
.6
 m
g/
kg
)
20
.0
 ±
 3
.8
22
.7
 ±
 4
.1
19
.0
 ±
 3
.5
16
.7
 ±
 2
.7
16
.1
 ±
 3
.3
*
15
.3
 ±
 2
.5
*
  H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
)
17
.2
 ±
 2
.2
17
.6
 ±
 2
.2
15
.1
 ±
 2
.4
15
.1
 ±
 2
.0
14
.5
 ±
 2
.6
13
.9
 ±
 1
.8
*
  H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
22
.5
 ±
 4
.4
21
.4
 ±
 5
.1
17
.9
 ±
 4
.4
16
.2
 ±
 3
.7
16
.2
 ±
 2
.3
*
16
.5
 ±
 3
.1
  P
IF
 (1
.5
 m
g/
kg
)
21
.3
 ±
 2
.8
21
.4
 ±
 2
.0
20
.1
 ±
 3
.2
17
.8
 ±
 2
.2
*
16
.5
 ±
 1
.5
*
17
.0
 ±
 2
.2
*
  P
IF
 (3
.0
 m
g/
kg
)
20
.6
 ±
 2
.4
19
.6
 ±
 3
.8
15
.3
 ±
 4
.4
*
15
.2
 ±
 3
.5
*
15
.4
 ±
 2
.3
*
15
.4
 ±
 2
.6
*
  H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
)
19
.6
 ±
 2
.8
19
.7
 ±
 4
.0
18
.7
 ±
 3
.0
16
.6
 ±
 2
.1
17
.2
 ±
 3
.1
15
.3
 ±
 2
.2
*
  H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
22
.6
 ±
 4
.4
22
.7
 ±
 4
.7
20
.1
 ±
 4
.0
19
.2
 ±
 5
.4
18
.1
 ±
 5
.0
17
.6
 ±
 4
.9
D
at
a 
ar
e 
m
ea
n 
± 
SD
.
Anesth Analg. Author manuscript; available in PMC 2008 October 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pagel et al. Page 12
H
R
 =
 h
ea
rt 
ra
te
; M
A
P 
= 
m
ea
n 
ar
te
ria
l p
re
ss
ur
e;
 R
PP
 =
 ra
te
 p
re
ss
ur
e 
pr
od
uc
t; 
C
O
N
 =
 c
on
tro
l; 
H
e 
= 
he
liu
m
; S
B
21
 =
 S
B
21
37
63
; P
IF
 =
 p
ifi
th
rin
-α 
; A
TR
 =
 a
tra
ct
yl
os
id
e.
* S
ig
ni
fic
an
tly
 (P
 ±
 0
.0
5)
 d
iff
er
en
t f
ro
m
 b
as
el
in
e.
Anesth Analg. Author manuscript; available in PMC 2008 October 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pagel et al. Page 13
Ta
bl
e 
2
Le
ft 
V
en
tri
cu
la
r A
re
a 
at
 R
is
k
N
B
od
y 
w
ei
gh
t (
g)
L
V
 (g
)
A
A
R
 (g
)
A
A
R
/L
V
 (%
)
C
O
N
7
27
69
 ±
 3
57
3.
61
 ±
 0
.2
8
1.
37
 ±
 0
.3
6
38
 ±
 8
H
e 
(1
 C
yc
le
)
7
27
36
 ±
 1
96
3.
45
 ±
 0
.2
3
1.
24
 ±
 0
.1
1
36
 ±
 5
H
e 
(3
 C
yc
le
s)
7
25
26
 ±
 1
43
3.
90
 ±
 0
.2
6
1.
30
 ±
 0
.0
7
34
 ±
 2
H
e 
(5
 C
yc
le
s)
6
26
47
 ±
 4
62
3.
55
 ±
 0
.3
4
1.
23
 ±
 0
.1
4
35
 ±
 2
SB
21
 (0
.2
 m
g/
kg
)
6
25
90
 ±
 2
94
3.
71
 ±
 0
.2
2
1.
61
 ±
 0
.1
4
44
 ±
 4
SB
21
 (0
.6
 m
g/
kg
)
7
26
71
 ±
 4
15
3.
56
 ±
 0
.3
1
1.
27
 ±
 0
.0
8
36
 ±
 3
H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
)
6
25
03
 ±
 1
33
3.
50
 ±
 0
.3
4
1.
30
 ±
 0
.0
8
37
 ±
 3
H
e 
(1
 C
yc
le
) +
 S
B
21
 (0
.2
 m
g/
kg
) +
 A
TR
 (5
 m
g/
kg
)
6
27
02
 ±
 1
32
3.
88
 ±
 0
.4
0
1.
44
 ±
 0
.2
7
37
 ±
 6
PI
F 
(1
.5
 m
g/
kg
)
7
25
63
 ±
 1
52
3.
36
 ±
 0
.4
9
1.
25
 ±
 0
.2
2
37
 ±
 4
PI
F 
(3
.0
 m
g/
kg
)
6
24
38
 ±
 1
03
3.
09
 ±
 0
.2
5
1.
22
 ±
 0
.0
4
40
 ±
 2
H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
)
6
24
28
 ±
 1
05
3.
07
 ±
 0
.1
9
1.
15
 ±
 0
.1
1
38
 ±
 3
H
e 
(1
 C
yc
le
) +
 P
IF
 (1
.5
 m
g/
kg
) ±
 A
TR
 (5
 m
g/
kg
)
7
27
20
 ±
 1
89
4.
19
 ±
 0
.2
7
1.
66
 ±
 0
.1
5
40
 ±
 4
D
at
a 
ar
e 
m
ea
n 
± 
SD
.
LV
 =
 le
ft 
ve
nt
ric
le
; A
A
R
 =
 a
re
a 
at
 ri
sk
; C
O
N
 =
 c
on
tro
l; 
H
e 
= 
he
liu
m
; S
B
21
 =
 S
B
21
37
63
; P
IF
 =
 p
ifi
th
rin
-α;
 A
TR
 =
 a
tra
ct
yl
os
id
e.
Anesth Analg. Author manuscript; available in PMC 2008 October 17.
